Novartis To Alert EU Doctors About Liver Failure Deaths In Zolgensma Patients
Executive Summary
The European Medicines Agency’s pharmacovigilance committee has reviewed the updated advice that EU prescribers will get on enhanced monitoring of spinal muscular atrophy patients treated with Zolgensma following fatal cases of acute liver failure.
You may also be interested in...
Zolgensma and Seven Other Products Get CHMP Thumbs Up
Zolgensma should receive a conditional approval, says the European Medicines Agency’s drug evaluation committee, the CHMP.
Global Medtech Guidance Tracker: January 2023
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Forty-eight documents have been posted on the tracker since its last update.
EU Regulators May Check Redactions In CTIS Documents To Boost Trial Transparency
A new EU guideline addresses numerous questions raised by study sponsors on processes for protecting commercial and personal data while using the Clinical Trials Information System.